Adam Mostafa Biography and Net Worth

CFO of X4 Pharmaceuticals

Mr. Mostafa has served as X4’s Chief Financial Officer since September 2018. Prior to joining X4, Mr. Mostafa served as chief financial officer of Abpro Corporation, a biotechnology company focused on antibody therapeutics. Prior to that, Mr. Mostafa was a managing director in the healthcare investment banking group at Cantor Fitzgerald, and was a senior banker in the healthcare investment banking group at Needham & Company. Prior to that, Mr. Mostafa was a vice president in the investment banking group at CRT Capital Group, and was a portfolio management associate in the global stock selection group at AQR Capital. He began his career as an analyst in the healthcare investment banking group at Salomon Smith Barney. Mr. Mostafa earned an A.B. in Economics from Brown University.

What is Adam S. Mostafa's net worth?: The estimated net worth of Adam S. Mostafa is at least $6.65 thousand as of February 12th, 2024. Mr. Mostafa owns 1,750 shares of X4 Pharmaceuticals stock worth more than $6,650 as of December 5th. This net worth evaluation does not reflect any other assets that Mr. Mostafa may own. Additionally, Mr. Mostafa receives an annual salary of $700,780.00 as CFO at X4 Pharmaceuticals. Learn More about Adam S. Mostafa's net worth.
How old is Adam S. Mostafa?: Mr. Mostafa is currently 44 years old. There are 8 older executives and no younger executives at X4 Pharmaceuticals. The oldest executive at X4 Pharmaceuticals is Dr. Robert David Arbeit, Senior Vice President of Clinical Development and Translational Research, who is 76 years old. Learn More on Adam S. Mostafa's age.
What is Adam S. Mostafa's salary?: As the CFO of X4 Pharmaceuticals, Inc., Mr. Mostafa earns $700,780.00 per year. The highest earning executive at X4 Pharmaceuticals is Dr. Paula Ragan Ph.D., CEO, President & Director, who commands a salary of $1,010,000.00 per year. Learn More on Adam S. Mostafa's salary.
How do I contact Adam S. Mostafa?: The corporate mailing address for Mr. Mostafa and other X4 Pharmaceuticals executives is 955 Massachusetts Avenue 4th Floor, Cambridge MA, 02139. X4 Pharmaceuticals can also be reached via phone at (857) 529-8300 and via email at [email protected]. Learn More on Adam S. Mostafa's contact information.
Has Adam S. Mostafa been buying or selling shares of X4 Pharmaceuticals?: Adam S. Mostafa has not been actively trading shares of X4 Pharmaceuticals during the past quarter. Most recently, Adam S. Mostafa sold 2,492 shares of the business's stock in a transaction on Friday, January 24th. The shares were sold at an average price of $13.50, for a transaction totalling $33,642.00. Learn More on Adam S. Mostafa's trading history.
Who are X4 Pharmaceuticals' active insiders?: X4 Pharmaceuticals' insider roster includes Mark Baldry (Chief Commercial Officer), Mary Dibiase (COO), Derek Meisner (General Counsel), Adam Mostafa (CFO), Paula Ragan (CEO), and Michael Wyzga (Director). Learn More on X4 Pharmaceuticals' active insiders.
Are insiders buying or selling shares of X4 Pharmaceuticals?: During the last twelve months, X4 Pharmaceuticals insiders bought shares 2 times. They purchased a total of 87,238 shares worth more than $252,556.76. During the last twelve months, insiders at the sold shares 4 times. They sold a total of 6,753 shares worth more than $91,165.50. The most recent insider tranaction occured on October, 23rd when Chairman Adam R Craig bought 86,206 shares worth more than $249,997.40. Insiders at X4 Pharmaceuticals own 2.4% of the company. Learn More about insider trades at X4 Pharmaceuticals.
Information on this page was last updated on 10/23/2025.

Adam S. Mostafa Insider Trading History at X4 Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/24/2025	Sell	2,492	$13.50	$33,642.00
10/7/2024	Sell	7,688	$16.50	$126,852.00
3/11/2024	Sell	1,750	$26.40	$46,200.00
2/12/2024	Sell	924	$30.30	$27,997.20	1,750
11/1/2023	Sell	7,688	$21.90	$168,367.20	2,674
6/30/2023	Sell	88	$56.70	$4,989.60	2,674
6/23/2023	Sell	180	$57.90	$10,422.00	2,762
6/15/2023	Sell	180	$66.60	$11,988.00	2,942
2/13/2023	Sell	924	$27.90	$25,779.60	4,873
8/17/2021	Sell	361	$153.00	$55,233.00
6/30/2021	Sell	88	$199.20	$17,529.60
6/24/2021	Sell	180	$210.30	$37,854.00	4,661
6/15/2021	Sell	180	$235.20	$42,336.00	4,300
9/21/2020	Sell	361	$212.40	$76,676.40
6/30/2020	Sell	57	$271.20	$15,458.40	294

Adam S. Mostafa Buying and Selling Activity at X4 Pharmaceuticals

X4 Pharmaceuticals Company Overview

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

Today's Range

Now: $3.80

$3.25

$3.81

50 Day Range

MA: $3.51

$2.86

$4.09

2 Week Range

Now: $3.80

$1.35

$26.83

Volume

655,802 shs

Average Volume

522,174 shs

Market Capitalization

$332.27 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.42

Adam Mostafa Biography and Net Worth

What is Adam S. Mostafa's net worth?

How old is Adam S. Mostafa?

What is Adam S. Mostafa's salary?

How do I contact Adam S. Mostafa?

Has Adam S. Mostafa been buying or selling shares of X4 Pharmaceuticals?

Who are X4 Pharmaceuticals' active insiders?

Are insiders buying or selling shares of X4 Pharmaceuticals?